Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Cell Mol Immunol ; 16(3): 314, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30635646

RESUMO

In this article, one of the grating agencies requested us to incorporate the information, Spanish Government and co-funded by European Union ERDF/ESF, "Investing in your future", in the acknowledgments section. The correct acknowledgement is as follows: "This work has been supported by grants of the Spanish Ministry of Health (Fondo de Investigaciones Sanitarias, PI13/00029, Spanish Government and co-funded by European Union ERDF/ESF, "Investing in your future"), Department of Education of Castilla and Leon Regional Government (Grant# LE093U13) and Mutua Madrileña Foundation (Basic research grants 2012) to J.I.R.B.; by Miguel Servet National Program (Ministry of National Health) CP12/03063 and by Gerencia Regional de Salud GRS963/A/2014 to M.L.R.G. We are particularly grateful to Mr. Leonides Alaiz for outstanding animal husbandry." The authors regret the errors.

2.
Cell Mol Immunol ; 14(6): 497-510, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26924526

RESUMO

The molecular pathways contributing to humoral-mediated allograft rejection are poorly defined. In this study, we assessed the role of the herpesvirus entry mediator/B- and T-lymphocyte attenuator (HVEM/BTLA) signalling pathway in the context of antibody-mediated allograft rejection. An experimental setting was designed to elucidate whether the blockade of HVEM/BTLA interactions could modulate de novo induction of host antidonor-specific antibodies during the course of graft rejection. To test this hypothesis, fully allogeneic major histocompatibility complex-mismatched skin grafts were transplanted onto the right flank of recipient mice that were treated with isotype control, anti-CD40L or modulatory antibodies of the HVEM/BTLA signalling pathway. The frequencies of CD4 T follicular helper (Tfh) cells (B220-, CD4+ CXCR5+ PD-1high), extrafollicular helper cells (B220-, CD4+ CXCR5- PD-1+ and PD-1-) and germinal centre (GC) B cells (B220+Fas+ GL7+) were analysed by flow cytometry in draining and non-draining lymph nodes at day 10 post transplantation during the acute phase of graft rejection. The host antidonor isotype-specific humoral immune response was also assessed. Whereas blockade of the CD40/CD40L pathway was highly effective in preventing the allogeneic humoral immune response, antibody-mediated blockade of the HVEM/BTLA-interacting pathway affected neither the expansion of Tfh cells nor the expansion of GC B cells. Consequently, the course of the host antidonor antibody-mediated response proceeded normally, without detectable evidence of impaired development. In summary, these data indicate that HVEM/BTLA interactions are dispensable for the formation of de novo host antidonor isotype-specific antibodies in transplantation.


Assuntos
Linfócitos B/imunologia , Centro Germinativo/imunologia , Rejeição de Enxerto/imunologia , Receptores Imunológicos/metabolismo , Membro 14 de Receptores do Fator de Necrose Tumoral/metabolismo , Transplante de Pele , Linfócitos T Auxiliares-Indutores/imunologia , Animais , Anticorpos Bloqueadores/administração & dosagem , Citotoxicidade Celular Dependente de Anticorpos , Antígenos CD40/imunologia , Ligante de CD40/imunologia , Feminino , Humanos , Imunidade Humoral , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Receptores Imunológicos/imunologia , Membro 14 de Receptores do Fator de Necrose Tumoral/imunologia , Transdução de Sinais , Transplante Homólogo
3.
Transl Res ; 181: 83-95.e3, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27702550

RESUMO

CD160 is a glycosylphosphatidylinositol-anchored protein of the immunoglobulin superfamily. It exhibits a pattern of expression coincident in humans and mice that is mainly restricted to cytotoxic cells and to all intestinal intraepithelial T lymphocytes. B- and T-lymphocyte attenuator (BTLA) and CD160 interact with cysteine-rich domain 1 of the extracellular region of Herpesvirus entry mediator (HVEM). CD160 engagement by HVEM can deliver inhibitory signals to a small subset of human CD4 T cells and attenuate its proliferation and cytokine secretion, but can also costimulate natural killer cells or intraepithelial lymphocytes. In turn, CD160 and BTLA can also function as agonist ligands being capable of costimulating T cells through membrane HVEM. Based on the restricted pattern of CD160 expression in cytotoxic cells, we postulated that CD160 may represent a suitable target for immune intervention in the setting of transplantation to modulate allogeneic cytotoxic responses. We demonstrated that in vivo administration of anti-CD160 antibody in combination with anti-CD40 L antibody to limit CD4 T-cell help modulated cytotoxic responses in a major histocompatibility complex class I mismatched model of allogeneic skin graft transplantation (bm1 donor to C57BL/6 recipient) and significantly prolonged graft survival. The implementation of this strategy in transplantation may reinforce current immunosuppression protocols and contribute to a better control of CD8 T-cell responses.


Assuntos
Antígenos CD/metabolismo , Citotoxicidade Imunológica , Sobrevivência de Enxerto/imunologia , Antígenos de Histocompatibilidade Classe I/metabolismo , Imunomodulação , Receptores Imunológicos/metabolismo , Transplante de Pele , Animais , Anticorpos Monoclonais/biossíntese , Antígenos CD/imunologia , Linfócitos T CD4-Positivos/imunologia , Ligante de CD40/metabolismo , Linfócitos T CD8-Positivos/imunologia , Linhagem Celular Tumoral , Feminino , Proteínas Ligadas por GPI/imunologia , Proteínas Ligadas por GPI/metabolismo , Células HEK293 , Humanos , Hibridomas/metabolismo , Memória Imunológica , Células Matadoras Naturais/imunologia , Linfonodos/metabolismo , Camundongos Endogâmicos C57BL , Receptores Imunológicos/imunologia
4.
MAbs ; 8(3): 478-90, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26752542

RESUMO

Tumor necrosis factor (TNF)/TNF receptor (TNFR) superfamily members play essential roles in the development of the different phases of the immune response. Mouse LIGHT (TNFSF14) is a type II transmembrane protein with a C-terminus extracellular TNF homology domain (THD) that assembles in homotrimers and regulates the course of the immune responses by signaling through 2 receptors, the herpes virus entry mediator (HVEM, TNFRSF14) and the lymphotoxin ß receptor (LTßR, TNFRSF3). LIGHT is a membrane-bound protein transiently expressed on activated T cells, natural killer (NK) cells and immature dendritic cells that can be proteolytically cleaved by a metalloprotease and released to the extracellular milieu. The immunotherapeutic potential of LIGHT blockade was evaluated in vivo. Administration of an antagonist of LIGHT interaction with its receptors attenuated the course of graft-versus-host reaction and recapitulated the reduced cytotoxic activity of LIGHT-deficient T cells adoptively transferred into non-irradiated semiallogeneic recipients. The lack of LIGHT expression on donor T cells or blockade of LIGHT interaction with its receptors slowed down the rate of T cell proliferation and decreased the frequency of precursor alloreactive T cells, retarding T cell differentiation toward effector T cells. The blockade of LIGHT/LTßR/HVEM pathway was associated with delayed downregulation of interleukin-7Rα and delayed upregulation of inducible costimulatory molecule expression on donor alloreactive CD8 T cells that are typical features of impaired T cell differentiation. These results expose the relevance of LIGHT/LTßR/HVEM interaction for the potential therapeutic control of the allogeneic immune responses mediated by alloreactive CD8 T cells that can contribute to prolong allograft survival.


Assuntos
Transferência Adotiva , Linfócitos T CD8-Positivos , Proliferação de Células , Transdução de Sinais/imunologia , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/imunologia , Animais , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/transplante , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Receptores de Interleucina-7/imunologia , Transdução de Sinais/genética , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/genética
5.
Nefrología (Madr.) ; 35(5): 457-464, sept.-oct. 2015. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-144800

RESUMO

Los pacientes con infección por el virus de la inmunodeficiencia humana (VIH) y enfermedad renal que terminan en tratamiento sustitutivo renal constituyen un grupo especial con interés creciente para la nefrología. Con el objetivo de conocer datos epidemiológicos de los pacientes VHI+ en España, recogimos información individualizada durante los años 2004 a 2011 (periodo de uso de tratamiento antiviral de alta eficacia) en las comunidades autónomas (CCAA) de Andalucía, Aragón, Asturias, Cataluña, Comunidad Valenciana, Castilla-La Mancha, Castilla y León, Galicia, Madrid, La Rioja y País Vasco, que comprendían un 85% de la población española. Se analizó a un total de 271 pacientes incidentes y 209 prevalentes. Se compararon con el resto de pacientes en tratamiento sustitutivo durante el mismo periodo de tiempo. La incidencia anual fue de 0,8 pacientes por millón de habitantes, con un aumento significativo a lo largo del periodo de seguimiento. La proporción de pacientes prevalentes VIH+ fue de 5,1/1.000 pacientes en tratamiento sustitutivo, intervalo de confianza (IC) del 95%: 4,4-5,8. Las causas glomerulares constituyeron la mayoría (42%), aunque hubo un 14% de nefropatía diabética. En el total de España, esos porcentajes son 13 y 25%, respectivamente. Comparando frente al total de pacientes en tratamiento, el riesgo de muerte fue significativamente mayor en el grupo VIH+: hazard ratio (HR) ajustado por edad, sexo y presencia de diabetes: 2,26 (IC 95%: 1,74-2,91). La coinfección por hepatitis C aumentó el riesgo de muerte dentro del grupo VIH+: HR 1,77 (IC 95%: 1,10-2,85). La probabilidad de recibir trasplante renal en los VIH+ solo alcanzó el 17% a los 7 años, comparando con el total de pacientes en diálisis HR: 0,15 (IC 95%: 0,10-0,24). A pesar del uso de las nuevas combinaciones de antivirales, la incidencia de pacientes VIH+ en diálisis se ha incrementado, su mortalidad supera todavía al resto de pacientes, y tienen una tasa de trasplante muy baja. Se hace necesario profundizar en el conocimiento de esta enfermedad para mejorar los resultados (AU)


Patients on renal replacement therapy (RRT) infected with the human immunodeficiency virus (HIV) are a special group with growing interest. In order to study the epidemiological data of HIV+ patients on RRT in Spain, we collected individual information from 2004-2011 (period of use of highly active antiretroviral therapy [HAART] in the Autonomous Communities of Andalusia, Aragon, Asturias, Catalonia, Valencia, Castilla la Mancha, Castilla León, Galicia, Madrid, La Rioja and the Basque Country, comprising 85% of the Spanish population. A total of 271 incident and 209 prevalent patients were analysed. They were compared with the remaining patients on RRT during the same period. The annual incidence was 0.8 patients per one million inhabitants, with a significant increase during the follow-up period. The proportion of prevalent HIV+ patientswas 5.1 per 1,000 patients on RRT (95% confidence interval [CI] 4.4-5.8. Although glomerular diseases constituted the majority of cases (42%), diabetic nephropathy was the cause in 14% of patients. The nation-wide totals for these percentages were 13 and 25%, respectively. Compared to the total of patients in treatment, the risk of death was significantly higher in the HIV+ group: hazard ratio (HR) adjusted for age, sex and diabetes was 2.26 (95% CI 1.74 - 2.91). Hepatitis C coinfection increased the risk of death in the HIV+ group (HR 1.77; 95% CI 1.10 - 2.85). The probability of kidney transplantation in HIV+ was only 17% after 7 years, comparing with total RTT patients (HR 0.15; 95% CI: 0.10-0.24). Despite the use of HAART, the incidence of HIV+ patients on dialysis has increased; their mortality still exceeds non-HIV patients, and they have a very low rate of transplantation. It is necessary to further our knowledge of this disease in order to improve results (AU)


Assuntos
Humanos , Insuficiência Renal Crônica/fisiopatologia , Infecções por HIV/complicações , Terapia de Substituição Renal , Infecções por HIV/tratamento farmacológico , Análise de Sobrevida , Antirretrovirais/uso terapêutico , Coinfecção/complicações , Hepatite B Crônica/epidemiologia , Hepatite C Crônica/epidemiologia , Fatores de Risco , Transplante de Rim/estatística & dados numéricos
6.
Nefrologia ; 35(5): 457-64, 2015.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-26409500

RESUMO

Patients on renal replacement therapy (RRT) infected with the human immunodeficiency virus (HIV) are a special group with growing interest. In order to study the epidemiological data of HIV+ patients on RRT in Spain, we collected individual information from 2004-2011 (period of use of highly active antiretroviral therapy [HAART] in the Autonomous Communities of Andalusia, Aragon, Asturias, Catalonia, Valencia, Castilla la Mancha, Castilla León, Galicia, Madrid, La Rioja and the Basque Country, comprising 85% of the Spanish population. A total of 271 incident and 209 prevalent patients were analysed. They were compared with the remaining patients on RRT during the same period. The annual incidence was 0.8 patients per one million inhabitants, with a significant increase during the follow-up period. The proportion of prevalent HIV+ patients was 5.1 per 1,000 patients on RRT (95% confidence interval [CI] 4.4-5.8. Although glomerular diseases constituted the majority of cases (42%), diabetic nephropathy was the cause in 14% of patients. The nation-wide totals for these percentages were 13 and 25%, respectively. Compared to the total of patients in treatment, the risk of death was significantly higher in the HIV+ group: hazard ratio (HR) adjusted for age, sex and diabetes was 2.26 (95% CI 1.74 - 2.91). Hepatitis C coinfection increased the risk of death in the HIV+ group (HR 1.77; 95% CI 1.10 - 2.85). The probability of kidney transplantation in HIV+ was only 17% after 7 years, comparing with total RTT patients (HR 0.15; 95% CI: 0.10-0.24). Despite the use of HAART, the incidence of HIV+ patients on dialysis has increased; their mortality still exceeds non-HIV patients, and they have a very low rate of transplantation. It is necessary to further our knowledge of this disease in order to improve results.


Assuntos
Infecções por HIV/complicações , Insuficiência Renal Crônica/complicações , Terapia de Substituição Renal , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Antirretroviral de Alta Atividade , Comorbidade , Nefropatias Diabéticas/complicações , Progressão da Doença , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Humanos , Incidência , Transplante de Rim/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Prevalência , Modelos de Riscos Proporcionais , Insuficiência Renal Crônica/epidemiologia , Insuficiência Renal Crônica/terapia , Espanha , Adulto Jovem
7.
Int J Environ Res Public Health ; 12(5): 4869-88, 2015 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-25950653

RESUMO

Mixed methods research is interesting to understand complex processes. Organ transplants are complex processes in need of improved final performance in times of budgetary restrictions. As the main objective a mixed method approach is used in this article to quantify the technical efficiency and the excellence achieved in organ transplant systems and to prove the influence of organizational structures and internal processes in the observed technical efficiency. The results show that it is possible to implement mechanisms for the measurement of the different components by making use of quantitative and qualitative methodologies. The analysis show a positive relationship between the levels related to the Baldrige indicators and the observed technical efficiency in the donation and transplant units of the 11 analyzed hospitals. Therefore it is possible to conclude that high levels in the Baldrige indexes are a necessary condition to reach an increased level of the service offered.


Assuntos
Atenção à Saúde/métodos , Transplante de Órgãos/métodos , Atenção à Saúde/normas , Modelos Teóricos , Transplante de Órgãos/normas
8.
Transplantation ; 98(11): 1165-74, 2014 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-25226173

RESUMO

BACKGROUND: Tumor necrosis factor/tumor necrosis factor receptor superfamily members conform a group of molecular interaction pathways of essential relevance during the process of T-cell activation and differentiation toward effector cells and particularly for the maintenance phase of the immune response. Specific blockade of these interacting pathways, such as CD40-CD40L, contributes to modulate the deleterious outcome of allogeneic immune responses. We postulated that antagonizing the interaction of LIGHT expression on activated T cells with its receptors, herpesvirus entry mediator and lymphotoxin ß receptor, may decrease T cell-mediated allogeneic responses. METHODS: A flow cytometry competition assay was designed to identify anti-LIGHT monoclonal antibodies capable to prevent the interaction of mouse LIGHT with its receptors expressed on transfected cells. An antibody with the desired specificity was evaluated in a short-term in vivo allogeneic cytotoxic assay and tested for its ability to detect endogenous mouse LIGHT. RESULTS: We provide evidence for the first time that in mice, as previously described in humans, LIGHT protein is rapidly and transiently expressed after T-cell activation, and this expression was stronger on CD8 T cells than on CD4 T cells. Two anti-LIGHT antibodies prevented interactions of mouse LIGHT with its two known receptors, herpesvirus entry mediator and lymphotoxin ß receptor. In vivo administration of anti-LIGHT antibody (clone 10F12) ameliorated host antidonor short-term cytotoxic response in wild type B6 mice, although to a lesser extent than that observed in LIGHT-deficient mice. CONCLUSION: The therapeutic targeting of LIGHT may contribute to achieve a better control of cytotoxic responses refractory to current immunosuppressive drugs in transplantation.


Assuntos
Herpesviridae/metabolismo , Receptor beta de Linfotoxina/metabolismo , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/metabolismo , Animais , Anticorpos Monoclonais/imunologia , Linfócitos T CD4-Positivos/citologia , Antígenos CD40/antagonistas & inibidores , Ligante de CD40/antagonistas & inibidores , Linfócitos T CD8-Positivos/citologia , Citometria de Fluxo , Células HEK293 , Humanos , Ativação Linfocitária , Camundongos , Células NIH 3T3 , Ligação Proteica , Estrutura Terciária de Proteína
9.
Xenotransplantation ; 20(6): 397-406, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23968542

RESUMO

Xenotransplantation is an innovative field of research with the potential to provide us with an alternative source of organs to face the severe shortage of human organ donors. For several reasons, pigs have been chosen as the most suitable source of organs and tissues for transplantation in humans. However, porcine xenografts undergo cellular immune responses representing a major barrier to their acceptance and normal functioning. Innate and adaptive xenogeneic immunity is mediated by both the recognition of xenogeneic tissue antigens and the lack of inhibition due to molecular cross-species incompatibilities of regulatory pathways. Therefore, the delivery of immunoreceptor tyrosine-based inhibitory motif (ITIM)-dependent and related negative signals to control innate (NK cells, macrophages) and adaptive T and B cells might overcome cell-mediated xenogeneic immunity. The proof of this concept has already been achieved in vitro by the transgenic overexpression of human ligands of several inhibitory receptors in porcine cells resulting in their resistance against xenoreactivity. Consequently, several transgenic pigs expressing tissue-specific human ligands of inhibitory coreceptors (HLA-E, CD47) or soluble competitors of costimulation (belatacept) have already been generated. The development of these robust and innovative approaches to modulate human anti-pig cellular immune responses, complementary to conventional immunosuppression, will help to achieve long-term xenograft survival. In this review, we will focus on the current strategies to enhance negative signaling pathways for the regulation of undesirable cell-mediated xenoreactive immune responses.


Assuntos
Imunidade Celular , Motivo de Ativação do Imunorreceptor Baseado em Tirosina/imunologia , Transplante Heterólogo , Animais , Antígenos Heterófilos , Rejeição de Enxerto/imunologia , Humanos , Motivo de Ativação do Imunorreceptor Baseado em Tirosina/genética , Células Matadoras Naturais/imunologia , Macrófagos/imunologia , Modelos Imunológicos , Transdução de Sinais/imunologia , Sus scrofa/genética , Sus scrofa/imunologia , Imunologia de Transplantes
10.
Nefrologia ; 28(2): 151-8, 2008.
Artigo em Espanhol | MEDLINE | ID: mdl-18454704

RESUMO

In 2005, renal replace treatment (dialysis and transplant) was necessary for about 40,000 people, without being known the number accurate and either their basic characteristics, such as: time in treatment, modality or treatment changes. The presented data cover the 76% of the Spanish population and are the result of the cooperation among technicians of registries, nephrologists and transplant coordinations. 4,125 people started RRT in 2005, the total estimated acceptance rate for renal replacement therapy in adults in Spain was 126 pmp and regarding other European countries it locates us in an intermediate area. The incidence rate seems to keep stable in the last years although there were some differences among communities (from 104 pmp in Castile and Leon to 186 pmp in Canary Islands). Diabetes Mellitus is the most diagnosed cause of renal failure in 2005, more than 20% of patients, followed by vascular diseases. The estimated prevalence of renal replacement therapy in Spain at the end of 2005 was 903 pmp, with important variations among communities (from 806 pmp in Cantabria to 1056 pmp in Valencia Region). The 47% of prevalent RRT patients had a functioning transplant. Mortality on haemodialysis and peritoneal dialysis was 13.7% and 10.8% respectively. Mortality on transplant was 1.3%, one of the lowest values registered so far. Mortality on renal replacement therapy was around 5% among patients from 45 to 64 years, 11% between 65 and 74 years and 19% among the patients older than 75 years.


Assuntos
Transplante de Rim/estatística & dados numéricos , Diálise Renal/estatística & dados numéricos , Adolescente , Adulto , Idoso , Humanos , Transplante de Rim/mortalidade , Pessoa de Meia-Idade , Diálise Renal/mortalidade , Espanha
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...